|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-10-10
|
|
pubmed:abstractText |
To develop a cycle-based risk prediction model for neutropenic complications (NC) during chemotherapy with doxorubicin (DOX) or a pegylated liposomal formulation (PLD) for patients with metastatic breast cancer (MBC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
369-74
|
|
pubmed:meshHeading |
pubmed-meshheading:18845996-Adult,
pubmed-meshheading:18845996-Aged,
pubmed-meshheading:18845996-Aged, 80 and over,
pubmed-meshheading:18845996-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18845996-Bone Neoplasms,
pubmed-meshheading:18845996-Breast Neoplasms,
pubmed-meshheading:18845996-Doxorubicin,
pubmed-meshheading:18845996-Female,
pubmed-meshheading:18845996-Humans,
pubmed-meshheading:18845996-Liver Neoplasms,
pubmed-meshheading:18845996-Lung Neoplasms,
pubmed-meshheading:18845996-Middle Aged,
pubmed-meshheading:18845996-Models, Statistical,
pubmed-meshheading:18845996-Neoplasm Recurrence, Local,
pubmed-meshheading:18845996-Neoplasm Staging,
pubmed-meshheading:18845996-Neutropenia,
pubmed-meshheading:18845996-Polyethylene Glycols,
pubmed-meshheading:18845996-Prognosis,
pubmed-meshheading:18845996-Prospective Studies,
pubmed-meshheading:18845996-Risk Factors,
pubmed-meshheading:18845996-Sensitivity and Specificity,
pubmed-meshheading:18845996-Survival Rate,
pubmed-meshheading:18845996-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
|
|
pubmed:affiliation |
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. gdranit@ca.inter.net
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
